Black Health
Thiazide diuretic Hypertension Edema

Hydrochlorothiazide (Microzide, HCTZ) and Black patients

Brand names: Microzide, HCTZ

Last reviewed: Sources checked:

What Hydrochlorothiazide does

Hydrochlorothiazide, usually written HCTZ, is a thiazide diuretic that makes the kidneys excrete more sodium and water, lowering blood pressure. It has been in use since the 1950s and is one of the cheapest and most widely prescribed blood-pressure medications in the world.

What the evidence says for Black patients

Thiazide-type diuretics are guideline-preferred first-line agents for Black adults with uncomplicated hypertension (2017 ACC/AHA, Whelton et al., 2018). Importantly, however, leading hypertension specialists increasingly recommend chlorthalidone or indapamide over HCTZ for several reasons that disproportionately affect Black patients:

  • Chlorthalidone has a much longer half-life (40–60 hours vs 8–15 hours) and produces more consistent 24-hour BP control, including lower nighttime BP — relevant because Black adults are more likely to be 'non-dippers' (lack the normal nighttime BP drop), which raises stroke risk.
  • ALLHAT, MRFIT, and SHEP — the trials that established thiazide-class mortality benefit — used chlorthalidone, not HCTZ. There is no equivalent outcome trial for HCTZ at the doses typically prescribed (12.5–25 mg).
  • A 2020 comparative effectiveness analysis (Hripcsak et al., JAMA Intern Med 2020;180:542–51, PMID 32065963) found no cardiovascular outcome benefit of HCTZ over chlorthalidone and slightly more hypokalemia with chlorthalidone.

That said, HCTZ at 12.5–25 mg does lower BP effectively in Black adults and is often chosen for cost and fixed-dose combination reasons (e.g., losartan-HCTZ, lisinopril-HCTZ).

Common alternatives

Chlorthalidone 12.5–25 mg is the first-line thiazide-type diuretic per most recent expert opinion. Indapamide is an acceptable alternative with similar BP effects and somewhat less metabolic impact. Loop diuretics (furosemide, torsemide) are not first-line for hypertension but are used when the patient also has heart failure or significant CKD (eGFR below 30).

Side effects

  • Low potassium (hypokalemia) — most common metabolic side effect
  • Low sodium (hyponatremia), particularly in older adults
  • Elevated uric acid — can precipitate gout
  • Elevated blood glucose — can worsen glycemic control in people with diabetes
  • Increased urination, especially in the first weeks
  • Photosensitivity; modestly increased risk of non-melanoma skin cancer with long-term use (Pedersen et al., J Intern Med 2018;283:97–104, PMID 29047203)

Factors that affect adherence

The main adherence issues are the early-treatment urination (which usually settles within 2–4 weeks), metabolic labs requiring follow-up visits, and the occasional gout flare that can sour patients on the drug. Generic HCTZ is inexpensive and universally covered.

Questions to ask your doctor

Bring this list to your next appointment.

  • Would chlorthalidone be a better choice for me than HCTZ?
  • When will we check my potassium and sodium?
  • If I have gout or diabetes, does that change whether I should take this?
  • Can I take this in the morning so I don't wake up at night to urinate?

References

  1. ALLHAT Officers. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981–2997. PMID 12479763.
  2. Hripcsak G, Suchard MA, Shea S, et al. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med. 2020;180:542–551. PMID 32065963.
  3. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Hypertension Guideline. Hypertension. 2018;71:e13–e115.
  4. Pedersen SA, Gaist D, Schmidt SAJ, et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer. J Intern Med. 2018;283:97–104. PMID 29047203.
  5. U.S. Food and Drug Administration. Microzide (hydrochlorothiazide) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s004lbl.pdf

Medical disclaimer

This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.

Read our editorial standards for how we source, review, and update these pages.